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The impact of immediate breast reconstruction on the time
to delivery of adjuvant therapy: the iBRA-2 study
Rachel L O’Connell1, Tim Rattay2, Rajiv V Dave3, Adam Trickey4, Joanna Skillman5, Nicola L. P. Barnes3, Matthew Gardiner6,7,
Adrian Harnett8, Shelley Potter 4,9 and Chris Holcombe10 on behalf of the iBRA-2 Steering Group and
the Breast Reconstruction Research Collaborative
BACKGROUND: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring
mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-
term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant
therapy.
METHODS: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient
demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first
adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored.
RESULTS: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n= 675, 26.6%];
pedicled flaps [n= 105,4.1%] and free-flaps [n= 228, 8.9%]). Complications requiring re-admission or re-operation were
significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy
was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient
groups but major complications irrespective of surgery received were significantly associated with treatment delays.
CONCLUSIONS: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are
associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve
outcomes for patients.
British Journal of Cancer (2019) 120:883–895; https://doi.org/10.1038/s41416-019-0438-1
BACKGROUND
Breast cancer is the most common female cancer worldwide with
1.7 million new cases diagnosed each year.1 Despite improve-
ments in treatment, however, mastectomy remains the primary
surgical treatment for almost 40% of women2,3 and immediate
breast reconstruction (IBR) is offered with the aim of improving
quality-of-life.4
Although psychosocial outcomes are an important consideration
when planning treatment, oncological safety remains paramount.
Breast reconstruction is associated with more complications than
simple mastectomy,5 and concerns have been raised that the
increased complication rate may lead to the delay or omission of
adjuvant chemotherapy or radiotherapy,6 which may compromise
oncological outcomes. The clinical significance of short delays is
unclear, but two recent large population-based studies have shown
that patients experiencing delays of more than 90 days in the
delivery of chemotherapy experienced worse overall and cancer-
specific survival.7,8 Furthermore, a recent meta-analysis suggests a
15% decrease in overall survival for every four-week delay in the
delivery of adjuvant chemotherapy.9 Delays to radiotherapy have
similarly adverse effects but the time-frames are less well-
established. A meta-analysis including 21 retrospective breast
cancer studies suggested an increased risk of loco-regional
recurrence if radiotherapy was delayed by more than 8 weeks
following surgery,10 but other large cohort studies have demon-
strated no deleterious effects with delays of up to 20 weeks.11
Evidence regarding the impact of IBR on the delivery of adjuvant
therapy, however, is inconsistent.6 A recent systematic review6
failed to demonstrate a clinically significant delay in the initiation of
chemotherapy but included 14 mainly single-centre studies with
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significant heterogeneity and these results cannot be relied upon.
Two large population-based studies, however have recently
reported delays to the start of chemotherapy in the patients
undergoing IBR. One study did not differentiate between types of
breast reconstruction7 and the second used patients undergoing
breast conserving surgery as a control group and demonstrated
delays in patients undergoing mastectomy without reconstruction
as well as those undergoing immediate autologous reconstruction
procedures8 making these findings difficult to interpret.
High-quality evidence regarding the impact of IBR on the
delivery of adjuvant therapy compared with mastectomy alone is
therefore lacking. Randomised trials (RCTs) provide the best
evidence of treatment effect but are inappropriate in this context.
A large-scale prospective cohort study is therefore required to
generate high-quality data to allow patients and surgeons to
make more informed decisions about potential treatment options.
The trainee research collaborative model has recently emerged as
a time and cost-effective method for delivering large-scale
prospective studies in reconstructive breast surgery.12 This
network of breast and plastic surgeons was utilised to deliver
the iBRA-2 study to determine the impact of IBR on the delivery of
adjuvant treatment.13
METHODS
Study design and participants
A prospective multicentre cohort study was used to determine
whether IBR influenced time to delivery of adjuvant therapy
compared to mastectomy alone.
All breast or plastic surgical units performing mastectomy with
or without IBR were invited to participate through the UK Trainee
Collaborative Research Network (the Mammary Fold Academic
and Research Collaborative and the Reconstructive Surgery Trials
Network) and the UK professional associations (Association of
Breast Surgery [ABS] and the British Association of Plastic
Reconstructive and Aesthetic Surgeons [BAPRAS]).
Consecutive women aged 18 or over undergoing mastectomy
with or without IBR using any technique for invasive or pre-
invasive (ductal carcinoma in situ, DCIS) breast cancer with
curative intent at participating centres between 1st July and 31st
December 2016 were recruited to the study. Excluded were
patients undergoing risk-reducing surgery (without a therapeutic
mastectomy for breast cancer), partial mastectomy including wide
local excision with volume replacement (latissimus dorsi mini-
flaps; lateral intercostal perforator (LICAP) or thoracodorsal artery
perforator (TDAP) flaps) or displacement techniques (therapeutic
mammaplasty), and those with distant metastatic disease.
This study was classified as service evaluation by the UK
National Health Service Research Authority Decision Tool (http://
www.hra-decisiontools.org.uk/research/index.html), hence indivi-
dual patient consent was not required. Each participating centre
registered the study and obtained local clinical governance
approvals before commencing patient recruitment. The study
protocol was published in 2016.13
Procedures
Patients were identified prospectively from clinics, multidisciplin-
ary team (MDT) meetings and operating theatre lists. Simple
demographic, comorbidity, operative and oncology data were
collected for each participant. Decisions regarding the recom-
mendation for adjuvant treatment were identified from the post-
operative MDT meeting.
For patients in whom adjuvant therapy was recommended,
data were collected on whether the offer was accepted and in
patients electing to receive adjuvant therapy, date of the first
treatment was recorded.
Data regarding post-operative complications were collected
prospectively until the patient commenced adjuvant therapy or it
was decided that adjuvant therapy would be omitted due to post-
operative complications. Preliminary work suggested that adju-
vant therapy was unlikely to commence earlier than 6 weeks post-
operatively. Data collection in patients not requiring adjuvant
treatment therefore continued from the last definitive cancer
surgery until 6 weeks following surgery either by clinical
assessment or note-review in those not attending for follow-up.
The REDCap electronic data-capture system14 (http://www.
projectredcap.org/) was used in data collection.
The study processes were piloted over a 4-week period to
ensure the feasibility of the study and to refine the case report
forms before commencing national recruitment.
For the purposes of the analysis, patients were categorised into
four groups according to the most complex procedure received
as: (i) mastectomy only without reconstruction; (ii) mastectomy
and IBR with implant-only techniques; (iii) mastectomy and IBR
with pedicled flaps and (iv) mastectomy and IBR with free-flap
techniques. Implant-based procedures included any reconstruc-
tion in which only expanders/implants were used to reconstruct
the breast. This included one or two-stage procedures with or
without biological (e.g. acellular dermal matrix) or synthetic (e.g.
titanium-coated polypropylene) mesh irrespective of whether the
implant/expander was placed in a pre- or subpectoral position.
Pedicled flap procedures included any pedicled flap used to
reconstruct the breast with or without an implant/expander and
included latissimus dorsi (LD) and transverse rectus abdominus
myocutaneous (TRAM) flaps. Free-flap procedures included any
technique in which a microvascular free-flap was used for IBR and
included deep inferior epigastric perforator (DIEP), superficial
inferior epigastric perforator (SIEA), superior and inferior gluteal
artery perforator (SGAP and IGAP) and transverse upper gracillis,
(TUG) procedures.
Outcome measures
The primary outcome was time in days from last definitive cancer
surgery to the first adjuvant treatment. The last definitive cancer
surgery included any additional procedures recommended by the
MDT for oncological reasons (e.g. axillary clearance) but did not
include any surgery for post-operative complications (e.g. debride-
ment of skin-flap necrosis). First adjuvant therapy was defined as the
first dose of chemotherapy or the first fraction of radiotherapy. Time
to endocrine therapy was not included. In patients for whom more
than one modality of adjuvant treatment was recommended, only
the start date for the first adjuvant therapy was recorded. Significant
treatment delays to (i) chemotherapy and (ii) radiotherapy were
defined based on the best available evidence7,8,10 as delays of
>90 days for chemotherapy7,8 and >8 weeks for radiotherapy.10
Secondary outcomes included post-operative complications, re-
admission to hospital following discharge and unplanned re-
operation for complications within 6 weeks of the last definitive
cancer surgery or prior to the start of adjuvant therapy. All
complications were defined a priori. Major complications were
defined as any complication requiring re-admission or re-
operation. Minor complications were defined as those managed
conservatively.13
Quality assurance
For quality assurance (QA) purposes, the principal investigator at
each participating site was asked to independently validate 5–10%
of the submitted data for each unit and to check complete case
ascertainment. If concordance between the data entered on
REDCap and that independently validated was <90%, the unit’s
data were excluded from the analysis consistent with the QA
procedure used in other collaborative projects.13
Statistical analysis
Descriptive summary statistics were calculated for each variable
for the cohort overall and split by operative procedure. Categorical
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Table 1. Demographics of participants in the iBRA-2 study by procedure type
All patients
(n= 2540)
Mastectomy only
(n= 1532, 60.3%)
Implant
(n= 675, 26.6%)
Pedicled flap
(n= 105, 4.1%)
Free-flap
(n= 228, 8.9%)
P-value
Age (years): median (IQR) (range) 58 (48–69)
(21–96)
65 (54–75) (26–96) 50 (43–57) (23–82) 52 (47–60) (25–74) 50 (44.5–56)
(21–72)
<0.001a
<35 89 (3.5) 34 (2.2) 42 (6.2) 4 (3.8) 9 (4.0)
35–44 337 (13.3) 115 (7.5) 160 (23.7) 14 (13.3) 48 (21.1)
45–54 655 (25.8) 257 (16.8) 248 (36.7) 50 (47.6) 100 (43.9)
55–64 537 (21.1) 320 (20.9) 141 (20.9) 22 (21.0) 54 (23.7)
65–75 509 (20.0) 406 (26.5) 71 (10.5) 15 (14.3) 17 (7.5)
>75 402 (15.8) 392 (25.6) 10 (1.5) 0 (0.0) 0 (0.0)
Not reported 11 (0.4) 8 (0.5) 3 (0.4) 0 (0.0) 0 (0.0)
BMI (median) kg/m2 26.4 27.3 24.4 26.6 27.4 <0.001a
(IQR) (range) (23.2–30.7)
(13.4–80.7)
(23.7–32.2) (13.4–80.7) (21.9–27.6)
(16.0–61.4)
(23.3–30.6)
(18.5–39.2)
(24.2–30.1)
(15.6–31.1)
Underweight 55 (2.2) 33 (2.2) 20 (3.0) 0 (0.0) 2 (0.9)
Normal 880 (34.7) 445 (29.0) 328 (48.6) 37 (35.2) 70 (30.7)
Overweight 769 (30.3) 457 (29.8) 191 (28.3) 35 (33.3) 86 (37.7)
Obese 380 (15.0) 252 (16.4) 65 (9.6) 22 (21.0) 41 (18. 0)
Severely obese 277 (10.9) 221 (14.4) 35 (5.2) 5 (4.8) 16 (7.0)
Not reported 179 (7.1) 124 (8.1) 36 (5.3) 6 (5.7) 13 (5.7)
Smoking status 0.015b
Non-smoker 1829 (71.6) 1082 (70.6) 499 (73.9) 75 (71.4) 163 (71.5)
Current smoker 276 (10.9) 180 (11.7) 73 (10.8) 12 (11.4) 11 (4.8)
Ex-smoker 401 (15.8) 241 (15.7) 91 (13.5) 18 (17.1) 51 (22.4)
Missing 44 (1.7) 29 (1.9) 12 (1.8) 0 (0.0) 3 (1.3)
Comorbidities
Diabetes 232 (9.1) 189 (12.3) 25 (3.7) 7 (6.7) 11 (4.8) <0.001b
Ischaemic heart disease 140 (5.5) 133 (8.7) 3 (0.4) 2 (1.9) 2 (0.9) <0.001b
Other comorbidity 1186 (46.7) 848 (55.3) 222 (32.9) 36 (34.3) 80 (35.1) <0.001b
Previous oncological therapy
Radiotherapy to ipsilateral breast 240 (9.5) 158 (10.3) 40 (5.9) 16 (15.2) 26 (11.4) 0.011b
Neoadjuvant chemotherapy 422 (16.6) 230 (15.0) 128 (19.0) 21 (20.0) 43 (18.9) 0.001b
Neoadjuvant endocrine therapy 186 (7.3) 136 (8.9) 28 (4.1) 8 (7.6) 14 (6.1) <0.001b
Previous surgery to ipsilateral breast
Any surgery 546 (21.5) 299 (19.5) 147 (21.8) 37 (35.2) 63 (27.6) 0.001b
Cosmetic surgery 32 (1.3) 7 (0.5) 17 (2.5) 1 (1.0) 7 (3.1) <0.001b
Oncological surgery 477 (18.7) 271 (17.7) 119 (17.6) 33 (31.4) 54 (23.7) 0.001b
Previous surgery to ipsilateral axilla
Any axillary surgery 502 (19.8) 230 (15.0) 148 (21.9) 40 (38.1) 84 (36.8) <0.001b
Axillary clearance 102 (4.0) 70 (4.6) 15 (2.2) 10 (9.5) 7 (3.1) <0.001b
Axillary sample 41 (1.6) 30 (2.0) 2 (0.3) 2 (1.9) 7 (3.1)
SNB (with BCS) 192 (7.6) 107 (7.0) 54 (8.0) 11 (10.5) 20 (8.8)
Stand-alone SNB 167 (6.6) 23 (1.5) 77 (11.4) 17 (16.2) 50 (21.9)
ASA grade <0.001b
Grade 1 705 (27.8) 333 (21.7) 273 (40.4) 40 (38.1) 59 (25.9)
Grade 2 1506 (59.3) 906 (59.1) 379 (56.2) 61 (58.1) 160 (70.2)
Grade 3 313 (12.3) 279 (18.2) 23 (3.4) 3 (2.9) 8 (3.5)
Grade 4 6 (0.2) 6 (0.4) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 10 (0.4) 8 (0.5) 0 (0.0) 1 (1.0) 1 (0.4)
Laterality of surgery <0.001b
Unilateral Mx ± BR 2235 (88.0) 1427 (93.2) 528 (78.2) 96 (91.4) 184 (80.7)
Bilateral Mx ± BR 189 (7.4) 71 (4.6) 98 (14.5) 1 (1.0) 19 (8.3)
Unilateral procedure +
contralateral symmetrisation
91 (3.6) 19 (1.2) 43 (6.4) 8 (7.6) 21 (9.2)
25 (1.0) 15 (1.0) 6 (0.9) 0 (0.0) 4 (1.8)
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data were summarised by counts and percentages. Continuous
data were summarised by median, interquartile range (IQR) and
range. Procedure groups were compared using appropriate non-
parametric statistics. Complications and oncological outcomes
were summarised by procedure and by patient.
Univariable and multivariable logistic regression analysis was
used to explore clinico-pathological variables hypothesised to be
associated with the development of (i) any complication and (ii)
major complications, as these were considered most likely to
impact on time to adjuvant therapy. Variables of interest were
defined a priori based on the literature and expert opinion and
included patient and procedure-related variables, namely age,
smoking, body mass index (BMI), diabetes, ischaemic heart disease
(IHD), other comorbidities, previous surgery and/or radiotherapy
to the ipsilateral breast; neoadjuvant chemotherapy (NAC),
American Society of Anesthesiologists (ASA) grade, unilateral vs
bilateral surgery, type of axillary surgery (none, sentinel node
biopsy [SNB] or axillary node clearance [ANC]) and procedure type
(mastectomy, implant-based, pedicled or free-flap reconstruction).
Time from surgery to first adjuvant therapy was calculated for
all patients and for those undergoing (i) chemotherapy and (ii)
radiotherapy as their first adjuvant treatment separately in each
procedure group, with adjuvant therapy as the event. This analysis
was repeated stratifying by whether the patient had no, minor, or
major complications. Kaplan–Meier analyses, univariable and
multivariable Cox survival models of time to first adjuvant therapy
and time to (i) chemotherapy and (ii) radiotherapy separately split
by procedure type were created, including patient age, BMI,
diabetes, IHD, other comorbidities, smoking, ASA grade, unilateral
vs bilateral surgery, procedure type and the presence of
complications (none, minor or major) as variables of interest,
clustered by centre. The Kaplan–Meier graphs of time to adjuvant
therapy were curtailed at 150 days, when only 10 patients remain
in follow-up, to better focus on the majority of patients.
STATA 15 (STATA, Inc., Texas) was used for all analyses.
RESULTS
In total, 2652 patients were recruited to the study from 76 centres
across the UK (n= 66), Europe (n= 9) and North Africa (n= 1). Of
these, 112 (4.4%) were excluded; 19 (0.7%) had surgery outside of
the study period; 55 (2.1%) had risk-reducing surgery only; 6
(0.2%) did not undergo a mastectomy and 24 (0.9%) had incorrect
or important missing data (e.g. operation date or procedure type).
Eight (0.3%) patients had ‘other’ forms of reconstruction. These
could not be appropriately categorised, hence were excluded.
2540 patients were therefore included in the analysis. Of these,
1008 (39.7%) underwent IBR with implant-based (n= 675),
pedicled flaps (n= 105) or free-flap (n= 228) techniques.
Patient demographics
Patient demographics are summarised in Table 1. Women
undergoing IBR were younger and had fewer comorbidities than
patients undergoing mastectomy only. More patients undergoing
IBR received NAC than those undergoing simple mastectomy and
patients undergoing IBR were more likely to have undergone an
up-front SNB before their reconstruction, particularly if they were
undergoing tissue-based procedures. Bilateral surgery for risk
reduction or symmetry was more common in patients undergoing
implant-based or free-flap reconstruction (Table 1).
Post-operative complications
The 2540 patients underwent 2732 procedures including 773
implant-based reconstructions (157 subpectoral expanders; 410 sub-
pectoral reconstructions with biological or synthetic mesh; 105
dermal-sling procedures and 98 prepectoral reconstructions), 106
pedicled flaps (62 autologous LD, 39 LD with implant, 2 pedicled
TRAM and 2 other) and 247 free-flap procedures (219 DIEPs, 16 free
TRAMs, 4 SIEA, 7 TUG flaps and 1 other). Details of complications by
procedure are summarised in supplementary table 1.
Overall, 929 (36.6%) of patients in the study experienced at least
one post-operative complication (Table 2). Univariable analysis
identified age, BMI, IHD, diabetes, having other comorbidities,
smoking, ASA grade and undergoing an ANC but not IBR as risk
factors associated with developing a post-operative complication
(Table 2). Age, BMI, having other comorbidities, smoking and
undergoing an ANC remained strongly associated with post-
operative complications in the multivariable model, whereas
undergoing bilateral surgery and free-flap reconstruction were
also identified as independent risk factors for complications in the
multivariable analysis.
Major complications which required re-admission to hospital or
further surgery (Table 2) were experienced by 221 (8.7%) of
patients. Implant-based and free-flap reconstruction, age, BMI,
smoking and bilateral surgery were associated with major
complications in the univariable analysis. All of these variables
except for age, remained strongly associated with major
complications in the multivariable model but implant-based
(adjusted odds ratio [aOR] 4.34, 95% confidence interval [CI]
2.35–7.99) and free-flap reconstruction (aOR 4.88, 95% CI
2.63–9.04) were the strongest predictors for major complications
in this analysis (Table 2).
Table 1 continued
All patients
(n= 2540)
Mastectomy only
(n= 1532, 60.3%)
Implant
(n= 675, 26.6%)
Pedicled flap
(n= 105, 4.1%)
Free-flap
(n= 228, 8.9%)
P-value
Unilateral procedure +
contralateral oncological
procedure
Indication for bilateral surgery
(n= 305)
<0.001b
Bilateral malignancy 82 (26.9) 39 (37.1) 36 (24.5) 0 (0.0) 7 (15.9)
Unilateral malignancy/
contralateral risk reduction
116 (38.0) 35 (33.3) 66 (44.9) 2 (22.2) 13 (29.6)
Unilateral malignancy/
contralateral symmetrisationc
93 (30.5) 20 (19.1) 42 (28.6) 7 (77.8) 24 (54.6)
Unilateral malignancy/other 14 (4.6) 11 (10.5) 3 (2.0) 0 (0.0) 0 (0.0)
ASA American Society of Anaesthesiologists, BCS breast conserving surgery, BMI body mass index, BR breast reconstruction, IQR interquartile range, Mx
mastectomy, SNB sentinel node biopsy
aKruskal–Wallis test
bChi-squared test
cIncludes simple mastectomy/reduction mammoplasty/mastopexy/augmentation and contralateral and reconstruction
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Adjuvant treatment recommendations and time to adjuvant
therapy
Table 3 summarises the post-operative pathology for the 2607
mastectomies performed for oncological indications. IBR was more
likely to be performed following mastectomy for extensive DCIS or
multifocal disease and in node-negative patients than simple
mastectomy resulting in fewer patients in the IBR group requiring
adjuvant chemotherapy or radiotherapy.
Overall, 1235 (48.6%) patients were offered and accepted
adjuvant treatment (Table 4). Time to adjuvant treatment differed
between the groups, with those undergoing free-flap procedures
having longer time to adjuvant therapy than those undergoing
Table 3. Post-operative histology in procedures performed for malignancy
All procedures performed
for cancer (n= 2607)
Mastectomy only
(n= 1564)
Implant
(n= 707)
Pedicled flap
(n= 105)
Free-flap
(n= 231)
P-value
Patients having NAC with a complete
pathological response (n= 408)
135 (32.0) 66 (29.1) 52 (41.9) 9 (42.9) 8 (22.2) 0.031
Invasive status <0.001
Pre-invasive disease 388 (14.8) 141 (9.0) 163 (23.1) 26 (24.8) 58 (25.1)
Invasive disease 2186 (83.9) 1413 (90.4) 533 (75.4) 77 (73.3) 163 (70.6)
Not reported 33 (1.3) 10 (0.36) 11 (1.6) 2 (1.9) 10 (4.3)
Focality 0.001
Unifocal disease 1740 (66.7) 1091 (69.8) 446 (63.1) 72 (68.6) 131 (56.7)
Multifocal disease 836 (32.1) 455 (29.1) 251 (35.5) 33 (31.4) 97 (42.0)
Not reported 31 (1.2) 18 (1.2) 10 (1.4) 0 (0.0) 3 (1.3)
Invasive disease (n= 2186) grade 0.045
Grade 1 179 (8.2) 98 (6.9) 58 (10.9) 7 (9.1) 16 (9.8)
Grade 2 1187 (54.3) 759 (53.7) 285 (53.5) 47 (61.0) 96 (58.9)
Grade 3 800 (36.6) 543 (38.4) 186 (24.1) 21 (27.3) 50 (30.7)
Not reported 20 (0.9) 13 (0.9) 4 (0.8) 2 (2.6) 1 (0.6)
Histological type 0.489
Ductal 1540 (70.5) 986 (69.8) 382 (71.7) 55 (71.4) 117 (71.8)
Lobular 373 (17.1) 246 (17.4) 89 (16.7) 10 (13.0) 28 (17.2)
Mixed 121 (5.5) 80 (5.7) 26 (4.9) 4 (5.2) 11 (6.8)
Other 141 (6.5) 95 (6.7) 34 (6.4) 6 (7.8) 6 (3.7)
Not reported 11 (0.5) 6 (0.4) 2 (0.4) 2 (2.6) 1 (0.6)
Tumour stage <0.001
Tis 388 (14.9) 141 (9.0) 163 (23.1) 26 (24.8) 58 (25.1)
T1a (<0.5 cm) 187 (7.2) 88 (5.6) 71 (10.0) 9 (8.6) 19 (8.2)
T1b (0.5–1 cm) 179 (6.9) 89 (5.7) 63 (8.9) 13 (12.4) 14 (6.1)
T1c (1–2 cm) 578 (22.2) 359 (23.0) 156 (22.1) 17 (16.2) 46 (19.9)
T2 (2–5 cm) 948 (36.4) 672 (43.0) 185 (26.2) 28 (26.7) 63 (27.3)
T3 (>5 cm) 272 (10.4) 190 (12.2) 55 (7.8) 9 (8.6) 18 (7.8)
Not reported 55 (2.1) 25 (1.6) 14 (2.0) 3 (2.9) 13 (5.6)
Lymphovascular invasion 637 (29.1) 435 (30.8) 134 (25.1) 22 (28.6) 46 (28.2) 0.141
ER <0.001
Positive 1738 (79.5) 1106 (78.3) 445 (83.5) 56 (72.7) 131 (80.4)
Negative 433 (19.8) 298 (21.1) 86 (16.1) 18 (23.4) 31 (19.0)
Unknown 15 (0.7) 4 (0.3) 2 (0.4) 3 (3.9) 1 (0.6)
HER-2 0.871
Positive 422 (19.3) 273 (19.3) 109 (20.5) 12 (15.6) 28 (17.2)
Negative 1686 (77.1) 1087 (76.9) 408 (76.6) 61 (79.2) 130 (79.8)
Unknown 78 (3.6) 53 (3.8) 16 (3.0) 4 (5.2) 5 (3.1)
Nodal status <0.001
N0 1663 (63.8) 905 (57.9) 523 (74.0) 71 (67.6) 164 (71.0)
N1 944 (36.2) 659 (42.1) 184 (26.0) 34 (32.4) 67 (29.0)
Pre-invasive disease (n= 388) 0.396
Low grade 27 (7.0) 7 (5.0) 12 (7.4) 1 (3.8) 7 (12.1)
Intermediate grade 90 (23.2) 38 (27.0) 38 (23.3) 5 (19.2) 9 (15.5)
High grade 269 (69.3) 95 (67.4) 112 (68.7) 20 (76.9) 42 (72.4)
Not reported 2 (0.5) 1 (0.7) 1 (0.6) 0 (0.0) 0 (0.0)
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mastectomy only, adjusted hazard ratio (aHR) 0.84 (95% CI
0.71–0.99) (Table 5, Fig. 1a). The absolute differences between
the median time to adjuvant treatment across the groups,
however, were small; 52 (IQR 41–66) days for mastectomy only
vs 57 (IQR 46–72) days for free-flap reconstruction (Table 5). The
development of complications (Fig. 1b) and obesity were also
associated with longer time to adjuvant therapy (Table 5). Median
time to first chemotherapy was 47 days, (IQR 37–59). There were
no significant differences in median time to chemotherapy or in
the proportions of patients experiencing delays of greater that
90 days between the treatment groups (Table 4) but free-flap
reconstruction (aHR 0.79, [95% CI 0.65–0.96]), major complications
(aHR 0.72, [95% CI 0.54–0.94]) and obesity (aHR 0.75, [95% CI
0.57–0.99]) were associated with having longer time to che-
motherapy in the multivariable model (Supplementary table 2).
Median time to first fraction of radiotherapy was 60 days (IQR
48–73) with no differences in either the median time to
radiotherapy or the proportion of patients experiencing significant
treatment delays, defined as >8 weeks, between procedure types
(Table 4). Major complications (aHR 0.70, [95% CI 0.53–0.93]) and
smoking (aHR 0.73, [95% CI 0.57–0.94]) were associated with
longer time to adjuvant radiotherapy in the multivariable model
with older patients and those who had received neoadjuvant
chemotherapy proceeding to radiotherapy more rapidly than
other patient groups (Supplementary table 3).
Time to first adjuvant therapy (P < 0.001), time to chemotherapy
(P < 0.001) and time to radiotherapy (P= 0.026), however all
differed by whether the patient had no, minor or major
complications, with an increasing trend seen across the three
groups (no complications 50 days [IQR 39–63]; minor complica-
tions 56 days [IQR 42.5–69]; major complications 57 days [IQR
46–73], Supplementary table 4). Furthermore, patients
experiencing complications were significantly more likely to
experience significant treatment delays, defined as delays of
>90 days for chemotherapy (n= 14, 3.6% of patients with no
complications vs n= 7, 13% of patients with major complications;
P= 0.011) and >8 weeks for radiotherapy (n= 222, 58.7% of
patients with no complications vs n= 29, 70.7% of patients with
major complications; P= 0.016, Supplementary table 4) than those
whose procedures were uncomplicated.
DISCUSSION
Although free-flap reconstruction was associated with a longer
time to adjuvant therapy than other procedure types, the absolute
differences in time to treatment between the surgical groups is
small. This study therefore suggests that IBR does not result in
clinically significant delays in the delivery of adjuvant therapy
compared to mastectomy alone. Complications, especially those
requiring re-admission or further surgery however, are important
and patients developing problems, irrespective of the procedure
performed, were more likely to experience significant delays to
both chemotherapy and radiotherapy in this analysis. The
apparent paradox of no treatment delay despite the higher rate
of major post-operative complications in the IBR group can be
explained by careful patient selection for reconstructive surgery.
Patients undergoing IBR were significantly younger and fitter, with
fewer ‘risk factors’ for complications than patients undergoing
mastectomy only and were less likely to require adjuvant
treatment than the mastectomy only group. This is because IBR
was more likely to be performed following mastectomy for
extensive DCIS than for high-risk invasive disease with upfront
axillary staging used to determine the likelihood that patients
would require adjuvant treatment before their reconstructive
Table 4. Multidisciplinary team (MDT) decision-making for adjuvant therapy
MDT decision-making per patient All patients
(n= 2540)
Mastectomy only
(n= 1532)
Implant
(n= 675)
Pedicled flap
(n= 105)
Free-flap
(n= 228)
P-value
Chemotherapy
Recommended by MDT 649 (25.6) 421 (27.5) 154 (22.8) 28 (26.7) 46 (20.2) <0.001
For discussion with patient 188 (7.4) 138 (9.0) 36 (5.3) 5 (4.8) 9 (3.9)
For oncotype DX testing 181 (7.1) 95 (6.2) 64 (9.5) 5 (4.8) 17 (7.5)
Not recommended by MDT 1509 (59.4) 872 (56.9) 415 (61.5) 67 (63.8) 155 (68.0)
Not reported 13 (0.5) 6 (0.4) 6 (0.9) 0 (0.0) 1 (0.4)
Radiotherapy
Recommended by MDT 909 (35.7) 614 (40.1) 198 (29.3) 35 (33.3) 62 (27.2) <0.001
For discussion with patient 125 (4.9) 86 (5.6) 19 (2.8) 1 (1.0) 19 (8.3)
Not recommended by MDT 1492 (58.7) 828 (54.0) 449 (66.5) 69 (65.7) 146 (64.0)
Not reported 14 (0.5) 4 (0.3) 9 (1.3) 0 (0.0) 1 (0.4)
Patient accepts adjuvant treatment (either
chemotherapy or radiotherapy or both)
1235 (48.6) 804 (52.5) 288 (42.7) 50 (47.6) 93 (40.8) <0.001
Time from last oncological procedure to
first adjuvant treatment (days) median
(IQR) (n= 1131)
53 (41–65) 52 (41–66) 51 (41–63) 57 (42–73) 57 (46–72) 0.026
Chemotherapy as 1st adjuvant treatment 627 (55.4) 409 (55.4) 147 (56.5) 25 (52.1) 46 (54.1) 0.939
Time from last oncological procedure to
1st chemotherapy (days) median (IQR)
47 (37–59) 47 (37–59) 46 (35–57) 46 (39–58) 57 (41–70) 0.063
Reported delays of >90 days of planned
chemotherapy (n= 637)
31 (4.9) 21 (5.1) 4 (2.7) 3 (11.5) 3 (6.5) 0.228
Radiotherapy as 1st adjuvant treatment 504 (44.6) 329 (44.6) 113 (43.5) 23 (47.9) 39 (45.9) 0.939
Time from last oncological procedure to
1st radiotherapy (days) median (IQR)
60 (48–73) 59 (48–73) 60 (45–68) 63 (53–85) 62 (50–76) 0.248
Reported delays of >56 days (8 weeks) of
planned radiotherapy (n= 616)
389 (63.2) 258 (62.8) 83 (61.9) 23 (79.3) 25 (59.5) 0.308
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procedure. This suggests that surgeons are cautious in offering IBR
to patients likely to require adjuvant treatment.15 These concerns
may reflect the impact of radiotherapy on the cosmetic outcome
of reconstruction,16 but may also highlight anxiety about potential
delays to adjuvant treatment with surgeons only opting to
perform IBR in patients considered low risk. This study provides
much-needed evidence to suggest that IBR does not lead to
clinically significant delays in carefully selected low risk patient
groups but does highlight that major complications can result in
significant treatment delays. This study therefore strongly
supports the need for careful patient selection to minimise
complications and careful communication of the risks of post-
operative problems and the potential oncological implication of
complications on treatment delays with patients considering
surgery. The higher risk of complications in patients undergoing
bilateral surgery will particularly inform discussions with patients
Table 5. Cox univariable and multivariable survival analyses for time to adjuvant treatment
Univariable Multivariable (N= 1018)
N (%) Hazard ratioa (95% confidence
intervals)
P-value Hazard ratioa (95% confidence
intervals)
P-value
Procedure type 1131
Mastectomy only 738 (65.3%) Reference Reference
Implant-based 260 (23.0%) 1.08 (0.90, 1.29) 0.42 1.07 (0.88, 1.31) 0.496
Pedicled flap 48 (4.2%) 0.74 (0.49, 1.11) 0.149 0.72 (0.47, 1.08) 0.114
Free-flap 85 (7.5%) 0.84 (0.73, 0.97) 0.019 0.84 (0.71, 0.99) 0.036
Post-operative complications 1131
None 685 (60.6%) Reference Reference
Minor complications 360 (31.8%) 0.80 (0.70, 0.92) 0.002 0.85 (0.73, 1.00) 0.046
Major complications 86 (7.6%) 0.68 (0.54, 0.86) 0.001 0.63 (0.49, 0.82) 0.001
Chemotherapy as first adjuvant
treatment
1131 1.79 (1.55, 2.06) <0.001 2.42 (2.09, 2.81) <0.001
Age 1128 1.00 (0.99, 1.00) 0.206 1.01 (1.00, 1.01) 0.058
BMI 1078
Underweight 28 (2.6%) 1.03 (0.67, 1.59) 0.878 0.98 (0.66, 1.47) 0.933
Normal weight 387 (35.9%) Reference Reference
Overweight 354 (32.8%) 0.99 (0.85, 1.15) 0.867 1.00 (0.85, 1.17) 0.953
Obese 188 (17.4%) 0.74 (0.65, 0.84) <0.001 0.76 (0.64, 0.89) 0.001
Severely obese 121 (11.2%) 0.72 (0.61, 0.85) <0.001 0.81 (0.67, 0.97) 0.023
Comorbidities
Ischaemic heart disease 1128
No 1079 (95.7%) Reference Reference
Yes 49 (4.3%) 0.69 (0.53, 0.89) 0.005 0.82 (0.57, 1.18) 0.279
Diabetes 1103
No 1002 (90.8%) Reference Reference
Yes 101 (9.2%) 0.78 (0.68, 0.90) 0.001 0.94 (0.79, 1.13) 0.53
Other comorbidity 1123
No 638 (56.8%) Reference Reference
Yes 485 (43.2%) 0.88 (0.75, 1.03) 0.109 0.86 (0.70, 1.07) 0.17
Smoking status 1115
Non-smoker 805 (72.2%) Reference Reference
Ex-smoker 170 (15.3%) 1.11 (0.92, 1.34) 0.275 1.18 (0.96, 1.44) 0.111
Current smoker 140 (12.6%) 0.95 (0.81, 1.11) 0.496 0.88 (0.72, 1.07) 0.186
Neoadjuvant chemotherapy 1121
No 829 (74.0%) Reference Reference
Yes 292 (26.1%) 0.99 (0.87, 1.11) 0.808 1.71 (1.44, 2.03) <0.001
ASA grade 1126
1 357 (31.7%) Reference Reference
2 654 (58.1%) 0.90 (0.78, 1.04) 0.154 1.09 (0.89, 1.33) 0.389
3 113 (10.0%) 0.85 (0.67, 1.08) 0.183 1.13 (0.78, 1.62) 0.524
4 2 (0.2%) 0.73 (0.61, 0.87) 0.001 1.37 (0.87, 2.14) 0.176
Bilateral surgery (vs none) 1131 0.92 (0.77, 1.10) 0.374 0.93 (0.75, 1.17) 0.546
ASA American Society of Anaesthesiologists, BMI body mass index
aaHR < 1= increased time to adjuvant treatment aHR > 1= shorter time to adjuvant treatment
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wishing to undergo simultaneous contralateral risk-reducing
mastectomy and gives a sound rationale for delaying such
surgery if adjuvant therapy is anticipated, particularly in implant-
based reconstruction.
The findings of this study are consistent with other work
suggesting that post-operative complications, rather than proce-
dure type, are the main predictor of adjuvant treatment delays.8
This focuses attention on the need to reduce complications to
improve outcomes for patients and is particularly relevant as
reconstruction rates are increasing.17 Despite more procedures
being performed, however, complications rates appear to be rising
with re-operation for complications more than double that seen in
the UK National Mastectomy and Breast Reconstruction Audit
(NMBRA).5 This is a cause for concern as complications not only
delay delivery of adjuvant treatments and but may also adversely
impact long-term oncological outcomes by promoting a systemic
inflammatory response.18 Implant-based procedures are now the
most commonly-performed technique19,20 and although data
from the NMBRA5 and the National Surgical Quality Improvement
Program21 suggest implant reconstruction may be associated with
fewer complications than other techniques, this study suggests
that complications following implant-based and autologous
reconstruction are broadly comparable. Reasons for this require
further evaluation but may reflect the recent adoption of single-
stage direct-to-implant mesh-assisted reconstruction in the UK,22
which may be associated with higher complication rates than the
traditional two-stage procedures23 favoured in the US.20 Risk
factors for complications, including smoking and high BMI are
consistent with those previously reported24,25 and highlight the
importance of careful patient selection if post-operative problems
are to be avoided.
This is the first large prospective multicentre study to explore
the impact of IBR on time to adjuvant therapy, but it has
limitations. Firstly, this is an observational study and risk of bias
must be considered. Consecutive patients undergoing mastect-
omy were recruited from participating centres but there were
baseline differences in the treatment groups. Although it was
possible to adjust for confounding factors such as age, BMI,
smoking and ASA grade in the regression analyses, it is acknowl-
edged that it is not possible to identify and control for all potential
confounders which may have impacted the results. The study
included patients from 76 centres across the UK and Europe and it
is the largest study of its kind, but it is possible that participating
units differed from those not taking part. However, this is unlikely,
as almost half of all the breast and plastic surgical units in the UK
elected to participate. A further consideration is that by only
reporting delay to initiation of treatment, this study may under-
estimate both the overall complication rate of IBR and the true
impact of reconstruction on the delivery of adjuvant therapy. This
is particularly relevant for patients having implant reconstruction
who may develop infection while receiving chemotherapy
requiring treatment to be modified or stopped completely and
the implant removed. Following patients during adjuvant treat-
ment was not feasible with the trainee collaborative study design,
but new collaborations with oncology trainees will allow these
issues to be addressed in the future. Finally, this short-term study
does not allow the long-term oncological impact of post-operative
complications or any delays in the delivery of adjuvant therapy to
be assessed. A data-linkage study to explore long-term oncolo-
gical outcomes at 5 and 10 years is planned, allowing these
important questions to be addressed. Therefore, although it is not
possible to establish causality with an observational study design,
RCTs in this setting are not possible and the iBRA-2 study provides
much-needed evidence to support decision-making for IBR when
adjuvant treatments may be needed.
The development of post-operative complications rather than
the type of procedure performed has emerged as the key
determinant of delays to the delivery adjuvant therapy in this
study. Immediate implant-based and free-flap reconstructions,
however, are associated with significantly higher rates of major
complications than mastectomy alone and this is an important
finding that should be fully discussed with patients considering
reconstructive surgery. Avoiding IBR in high-risk patients including
smokers and those with a high BMI and not performing
unnecessary bilateral surgery may represent a simple strategy
for reducing post-operative problems but this approach needs
balanced against patients’ desire for IBR. Accurate and balanced
communication of risks and benefits is a vital part of shared
decision-making,26 and this study provides further evidence to
inform this discussion. Major complications, irrespective of the
procedure performed, result in delays to adjuvant treatment,
hence strategies to minimise complications are needed for all
patients undergoing breast cancer surgery to improve oncological
outcomes,18 quality-of-life27 and minimise the overall cost of
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care.28 Standardising care may be one strategy by which
outcomes may be improved and standardisation is the focus of
the UK ‘Getting it Right First Time’ initiative. http://
gettingitrightfirsttime.co.uk/surgical-specialty/breast-surgery/.
Other strategies include altering treatment sequencing and
routinely using neoadjuvant rather than adjuvant chemotherapy
in patients electing to undergo IBR. This approach is safe, and
these data show that those having neoadjuvant therapy start their
adjuvant therapy sooner. It may also allow patients to address
modifiable risk factors such as obesity or smoking before surgery
although it is appreciated that these changes may be challenging.
Increased use of neoadjuvant endocrine therapy may also have
utility in high-risk groups. Neoadjuvant radiotherapy is a novel
approach, which may provide an alternative treatment pathway in
patients in whom radiotherapy is likely to be required.29 More
accurately determining which patients may benefit from adjuvant
therapy before the start of their breast cancer treatment, however
may be the optimal solution and work to develop a more
personalised approach using molecular markers and gene
signatures is likely to reduce the number of future patients in
whom adjuvant treatment may be indicated.30,31
IBR does not delay the delivery of adjuvant therapy, but
implant-based and free-flap reconstructions are associated with
higher rates of post-operative complications which are associated
with treatment delays. Careful patient selection combined with
accurate communication of risk are therefore vital if patients are to
make fully informed decision about IBR when adjuvant therapy is
likely to be needed. Further strategies to minimise the risk of
complications such as increased use of neoadjuvant treatment
may also be beneficial in this group. This study provides important
information about the risk and impact of complications in IBR to
help patients and surgeons make more informed decisions about
their treatment options.
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